# Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas

> **NCT03603379** · PHASE1 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 9 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** C225-ILs-dox

## Key facts

- **NCT ID:** NCT03603379
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-16
- **Primary completion:** 2020-11-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603379, "Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03603379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*